Skip to main content
Premium Trial:

Request an Annual Quote

Proteome and Egenix to Develop Semen-Screening Diagnostic for Prostate Cancer

NEW YORK, March 7 (GenomeWeb News) - Proteome and Egenix will co-develop a semen-based diagnostic kit for prostate cancer, Proteome said today.


The non-invasive test will be based on the human carcinoma antigen.


Under the agreement, Egenix will fund research to optimize the detection of HCA in semen of prostate cancer patients. The companies will then share the rights for further development and commercialization of the test.


Egenix estimated a potential US market size for the HCA test of up to $1.5 billion, according to a statement.


"We initially wondered if there would be social or cultural objections to a test that requires the patient to provide an ejaculate specimen," said Egenix president Jedd Levine. "But it's common to look in organ secretions for signs of cancer in that organ and ... most men would willingly provide a semen specimen to potentially avoid a painful needle biopsy."

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.